Patrizia Aruta

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis: @TheLancet

🥸Plavix for secondary prevention may be superior to aspirin

😱 Summary

👇👇👇

[Daniele Giacoppo @DanieleGiacoppo]

Pivotal #Lancet publication simultaneous to #ESC2025! @vlgmrc @FeliceGragnano @Drroxmehran

Secondary prevention with clopidogrel reduces ischemic events without increasing bleeding compared with aspirin.

https://t.co/Z4EAJ6ywBe

[Daniele Giacoppo @DanieleGiacoppo]

#ESC2025 #Lancet @vlgmrc @FeliceGragnano @Drroxmehran

New IPD meta-analysis of 7 RCTs comparing clopidogrel with aspirin for secondary prevention in 28,982 patients.

https://t.co/DEwVIPel5Q

Building on consistent recent findings after PCI!

https://t.co/RFXzrabBmP

[RTHahnMD @hahn_rt]

Access free for 50 days our SOTA https://t.co/frNjlmGNrH The Last Decade in
Tricuspid Regurgitation: How Imaging Shaped a Field @lpbadano @denisamuraru @FabienPraz @NAjmoneMarsan @VDelgadoGarcia @j_hausleiter @JACCJournals @escardio @ACCinTouch

[Giulia Passaniti @PassanitiGiulia]

Out now!
Check out our review on
3D Echo in T-TEER
@LucySafi @AntoninoDiFran1

[Alexander Mladenow MD @alex1708ander]

#echofirst How to predict SAM after MV-repair ➡️ What to measure in the preprocedural TEE

ASE Guidelines for the Use of TEE to Assist with Surgical Decision-Making in the OR

@ASE360 #CVImaging

https://t.co/N9aQI30QfI

[Ritu Thamman MD @iamritu]

Congratulations @denisamuraru on being president elect of @EACVIPresident
Outstanding choice & look forward to your leadership!!!

[Denisa Muraru @denisamuraru]

Pre-registration for childcare services at #EuroEcho2024 now open

For more details:

https://t.co/g8E1qTEx63

@Sarah_Moharem @EACVIPresident @LunaGargani @DrGEMandoli @ElenaGalli10

[Andrea Scotti @AndreaScotti21]

💥Screening for TTVI: A Call for Innovation to Close the Eligibility Gap
@JACCJournals

🌐Eligibility for T-TEER vs. TTVR in a real-world setting

🔗 Editorial https://t.co/AqKARkrY2g

@azeemlatib
@MonteHeart @MontefioreNYC @EinsteinMed
#CardioED #MedEd

[Davide Capodanno @DFCapodanno]

I wrote the Comment on the INFINITY-SWEDEHEART trial for @TheLancet.

Drug-eluting stents still have limitations that raise concerns over a patient's lifetime, and avoiding the caging of the coronary arteries has become a central goal in developing the next generation of coronary devices.

Should the benefits of coronary bioadaptors be confirmed over time and across more complex patient populations, this novel technology could offer the long-awaited solution to flatten the event curve for patients with stent implants. #TCT2024

https://t.co/VFApp6MLIP

[Denisa Muraru @denisamuraru]

RAC sign by transesophageal #echofirst

Very nice example to keep in mind and recognize by TEE

[Luigi @lpbadano]

EACVI 2024–2026 elections are now taking place. Cast your vote to shape the association's future. I voted to contribute to its definition. #EACVI

[Luna Gargani @LunaGargani]

You can vote for EACVI elections!
There are many excellent candidates who will shape the future of our Association.

All my support to Prof. Denisa Muraru, candidate for President-Elect.

An outstanding scientist who has worked so hard for #EACVI with passion and determination.

[EHJCVI Editor-in-Chief @EHJCVIEiC]

Most read #EHJCVI Stress #echofirst in chronic coronary syndromes : a clinical consensus statement ➡️ https://t.co/Tg0gFVRjIM @ESC_Journals @escardio @bernhard_gerber @alessia_gimelli @leylaelifsade @Ivan_Echocardio @PalMaurovich @VDelgadoGarcia @EACVIPresident @ShehabAnwer

[Denisa Muraru @denisamuraru]

NEW from #EACVI!
🎯 Ready to elevate your #CVI research? This guide is your essential resource for understanding how to design, implement, and optimize clinical studies in #CVI.
Take advantage of these practical insights! 📑

https://t.co/DSbjeP7Rd4

#echofirst #whyCMR #yesCCT #Cardiology #Imaging #ClinicalResearch @Ivan_Echocardio @PalMaurovich @ESC_Journals @EHJCVIEIC @bernhard_gerber

[RTHahnMD @hahn_rt]

Second T-TEER randomized trial: Tri-FR! Presented at #ESC2024 #ESCCongress2024 by @DonalErwan showing similar TRILUMINATE results: primary 1Yr endpoint driven by QoL but numerically lower mortality and HFH. Longer FU needed. @ESCardioNews @escardio

[Hany Ragy @Hragy]

I totally love this slide!! Can you harm a patient by doing an echo?
Absolutely!!
#ESCCongress

[Davide Capodanno @DFCapodanno]

How many times have we seen this flow chart on the duration of DAPT change over the years? Let’s summarize the situation regarding class I recommendations (“must be done”) as reported in the new 2024 guidelines on chronic coronary syndromes:
- High bleeding risk patient: DAPT for 1-3 months.
- High ischemic risk patient with no high bleeding risk: DAPT for 6 months (alternatively 1-6 months in class IIb).
- Patient with neither high ischemic risk nor high bleeding risk: DAPT for 6 months (alternatively 1-3 months in class IIb).
I believe there is a missed opportunity for a recommendation regarding 'bi-risk' patients, but there is little evidence on this matter.
https://t.co/7RI6XRsdrd #ESCCongress

[Michele Tomaselli @michetomaselli]

Check out our latest review on #JASE about the strengths and limitations of echocardiographic parameters in assessing patients with TR before and after interventions. Great collaborative effort! https://t.co/kRJRxpNhyh
@lpbadano
@denisamuraru
@NAjmoneMarsan
@XGalloo
@CHPedroLi

[European Society of Cardiology Journals @ESC_Journals]

Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement in #EHJ. Read more 👉 https://t.co/X9bgp0DLkc

#ACVC_ESC #EAPCI @RoccoMontone @ehj_ed @thiele_holger